| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
RU-24969 hemisuccinate targets serotonin (5-HT) receptors, particularly the 5-HT1B and 5-HT2B subtypes. It acts as an agonist at these receptors, activating serotonergic signaling pathways. By binding to and activating 5-HT1B and 5-HT2B receptors, it modulates neurotransmitter release, smooth muscle contraction, and other physiological processes.
|
|---|---|
| ln Vitro |
RU 24969 With a pD2 of 7.45 at 1 μM, succinate (30 nM-1 μM) suppresses tritium efflux generated by K+ [1].
RU-24969 hemisuccinate is a potent agonist at 5-HT1B and 5-HT2B receptors. It has high affinity for these receptors and activates downstream signaling pathways. Its activity is characterized by its ability to stimulate receptor-mediated responses, such as inhibition of neurotransmitter release (via 5-HT1B) or smooth muscle contraction (via 5-HT2B). Specific IC50 or EC50 values are not detailed in the available literature. |
| ln Vivo |
Addict agent induction is enhanced by RU 24969 Succinate (1 mg/kg and 3 mg/kg; subcutaneous injection, once) [2]. RU 24969 Succinate: (0.03–3.0 mg/kg; 1 dosage administered subcutaneously) Dosage
RU-24969 hemisuccinate has been used in vivo to study the role of 5-HT1B and 5-HT2B receptors in various physiological processes. It has been shown to modulate behavior, cardiovascular function, and gastrointestinal motility. However, specific in vivo data and protocols are not detailed in the available literature. |
| Enzyme Assay |
The in vitro activity of RU-24969 hemisuccinate is assessed using radioligand binding assays. Membrane preparations from cells expressing 5-HT1B or 5-HT2B receptors are incubated with a labeled ligand in the presence of various concentrations of the compound. The Ki values are calculated from displacement curves.
|
| Cell Assay |
The agonist activity of RU-24969 hemisuccinate is assessed in functional cell-based assays. Cells expressing 5-HT1B or 5-HT2B receptors are treated with various concentrations of the compound. Receptor activation is measured by assessing the inhibition of forskolin-stimulated cAMP accumulation (for 5-HT1B, coupled to Gi) or by measuring calcium mobilization (for 5-HT2B, coupled to Gq). EC50 values are calculated from dose-response curves.
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rats injected with cocaine [2]
Doses: 1 and 3 mg/kg Route of Administration: subcutaneous injection; Doses: 1 and 3 mg/kg. 1 and 3 mg/kg, one time Experimental Results: cocaine-induced increase in dopamine DA levels in the nucleus accumbens (NAcc) and decrease in GABA levels in the ventral tegmental area (VTA). RU-24969 hemisuccinate has been evaluated in animal models to study the role of 5-HT1B and 5-HT2B receptors in behavior, cardiovascular function, and gastrointestinal motility. In these studies, the compound is typically administered systemically, and its effects on relevant physiological or behavioral endpoints are assessed. |
| ADME/Pharmacokinetics |
RU-24969 hemisuccinate has a molecular weight of approximately 398.4 and a molecular formula of C15H17N3O·C4H4O4. It is the hemisuccinate salt form of RU-24969, designed to improve solubility and stability. Purity is typically ≥98%. The compound is soluble in DMSO. Storage is recommended at -20°C.
|
| Toxicity/Toxicokinetics |
RU-24969 hemisuccinate is a research compound and its full toxicological profile is not detailed in the available literature. As a potent serotonin receptor agonist, it has the potential to cause serotonin syndrome at high doses and may affect cardiovascular and gastrointestinal function. Standard safety precautions should be followed when handling the compound.
|
| References |
[1]. Middlemiss DN. The putative 5-HT1 receptor agonist, RU 24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-HT autoreceptor. J Pharm Pharmacol. 1985 Jun;37(6):434-7.
[2]. Parsons LH, et al. RU 24969, a 5-HT1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse. 1999 May;32(2):132-5. [3]. Peroutka SJ. Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem. 1986 Aug;47(2):529-40. [4]. Aronsen D, et al. RU 24969-produced adipsia and hyperlocomotion: differential role of 5HT 1A and 5HT 1B receptor mechanisms. Pharmacol Biochem Behav. 2014 Sep;124:1-4. |
| Additional Infomation |
RU-24969 hemisuccinate (CAS#: 107008-28-6) is a potent serotonin receptor agonist with high affinity for 5-HT1B and 5-HT2B receptors. It is used as a research tool in neuropharmacology to study serotonergic signaling pathways and the role of 5-HT1B and 5-HT2B receptors in various physiological and pathological processes. The hemisuccinate salt form improves solubility and stability for research applications.
|
| Molecular Formula |
C32H38N4O6
|
|---|---|
| Molecular Weight |
574.68
|
| Exact Mass |
574.279
|
| CAS # |
107008-28-6
|
| Related CAS # |
RU 24969;66611-26-5
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
434.6ºC at 760mmHg
|
| Flash Point |
216.7ºC
|
| LogP |
5.699
|
| SMILES |
N1C2C=CC(OC)=CC=2C(C2CCNCC=2)=C1.C(O)(=O)CCC(O)=O.N1C2C=CC(OC)=CC=2C(C2CCNCC=2)=C1
|
| Synonyms |
RU 24969; RU24969; RU-24969
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~120 mg/mL (~346.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7401 mL | 8.7005 mL | 17.4010 mL | |
| 5 mM | 0.3480 mL | 1.7401 mL | 3.4802 mL | |
| 10 mM | 0.1740 mL | 0.8700 mL | 1.7401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
